Onivyde is a chemotherapy drug used to treat pancreatic cancer. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1].
How is Onivyde administered?
Onivyde is given intravenously [1].
What types of pancreatic cancer does Onivyde treat?
Onivyde is approved for use in patients with metastatic adenocarcinoma of the pancreas. It is typically used in combination with other chemotherapy agents like fluorouracil and leucovorin [1].
What are the potential side effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis. More serious side effects can include severe diarrhea, myelosuppression (low blood cell counts), and hypersensitivity reactions [1].
When did Onivyde receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Onivyde in February 2016 [1].
What is the mechanism of action for Onivyde?
Onivyde works by delivering irinotecan to tumor cells. Irinotecan is converted to SN-38, which inhibits topoisomerase I, an enzyme necessary for DNA replication and repair. This leads to DNA damage and cell death in cancer cells [1].
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde is often used in patients who have already received a gemcitabine-based chemotherapy regimen. Clinical trials have shown that Onivyde in combination with fluorouracil and leucovorin can improve overall survival compared to fluorouracil and leucovorin alone in this patient population [1].
What are the patent and exclusivity details for Onivyde?
Information regarding Onivyde's patent and exclusivity status can be found on DrugPatentWatch.com [2].
Are there any generic alternatives to Onivyde?
As a liposomal formulation, the development of generic alternatives can be complex. The patent and exclusivity landscape, as tracked by DrugPatentWatch.com, would indicate when such alternatives might become available [2].